These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27400247)

  • 1. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
    Navada SC; Silverman LR
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
    Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
    Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
    Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.
    Garcia-Manero G; Fenaux P; Al-Kali A; Baer MR; Sekeres MA; Roboz GJ; Gaidano G; Scott BL; Greenberg P; Platzbecker U; Steensma DP; Kambhampati S; Kreuzer KA; Godley LA; Atallah E; Collins R; Kantarjian H; Jabbour E; Wilhelm FE; Azarnia N; Silverman LR;
    Lancet Oncol; 2016 Apr; 17(4):496-508. PubMed ID: 26968357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
    Navada SC; Garcia-Manero G; OdchimarReissig R; Pemmaraju N; Alvarado Y; Ohanian MN; John RB; Demakos EP; Zbyszewski PS; Maniar M; Woodman RC; Fruchtman SM; Silverman LR
    Leuk Res; 2020 Jul; 94():106369. PubMed ID: 32442785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.
    Komrokji RS; Raza A; Lancet JE; Ren C; Taft D; Maniar M; Wilhelm F; List AF
    Br J Haematol; 2013 Aug; 162(4):517-24. PubMed ID: 23789936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel therapies for higher-risk myelodysplastic syndromes].
    Nannya Y
    Rinsho Ketsueki; 2018; 59(10):2058-2066. PubMed ID: 30305509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
    Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
    Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
    Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
    Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.
    Nazha A; Sekeres MA; Komrokji R; Steensma DP; Kantarjian H; Roboz G; Fenaux P; Prebet T; Azarnia N; Zbyszewski PS; Fruchtman SM; Santini V; Silverman LR; Platzbecker U; Garcia-Manero G
    Blood Cancer J; 2017 Dec; 7(12):644. PubMed ID: 29238044
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
    Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
    Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Established and emerging targeted therapies in the myelodysplastic syndromes.
    Canaani J; Nagler A
    Expert Rev Hematol; 2016 Oct; 9(10):997-1005. PubMed ID: 27615383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes.
    Montalban-Bravo G; Garcia-Manero G; Jabbour E
    Curr Opin Hematol; 2018 Mar; 25(2):146-153. PubMed ID: 29266015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.
    Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S56-9. PubMed ID: 26297279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
    Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
    Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
    Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
    Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
    Santini V; Prebet T; Fenaux P; Gattermann N; Nilsson L; Pfeilstöcker M; Vyas P; List AF
    Leuk Res; 2014 Dec; 38(12):1381-91. PubMed ID: 25444075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan AM; Salimi T; Epstein RS
    Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.
    Zeidan AM; Stahl M; Sekeres MA; Steensma DP; Komrokji RS; Gore SD
    Cancer; 2017 Oct; 123(19):3662-3672. PubMed ID: 28759108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.